Natera (NASDAQ:NTRA) Given New $200.00 Price Target at JPMorgan Chase & Co.

Natera (NASDAQ:NTRA) had its target price increased by JPMorgan Chase & Co. from $160.00 to $200.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the medical research company’s stock.

Several other analysts have also recently weighed in on NTRA. Morgan Stanley raised their target price on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Piper Sandler raised their price objective on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. TD Cowen boosted their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $147.50.

Natera Stock Performance

Shares of NTRA stock opened at $166.55 on Friday. Natera has a 52 week low of $57.22 and a 52 week high of $175.63. The firm has a 50 day moving average of $144.02 and a two-hundred day moving average of $124.46. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.95) EPS. On average, research analysts predict that Natera will post -1.61 EPS for the current fiscal year.

Insider Activity

In other Natera news, Director Rowan E. Chapman sold 1,767 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total transaction of $300,814.08. Following the transaction, the director now owns 6,202 shares in the company, valued at approximately $1,055,828.48. The trade was a 22.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the transaction, the chief executive officer now owns 195,686 shares of the company’s stock, valued at $25,141,737.28. The trade was a 2.50 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,987 shares of company stock valued at $21,895,591. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in the business. Itau Unibanco Holding S.A. purchased a new stake in Natera in the 2nd quarter valued at approximately $28,000. Quarry LP lifted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC increased its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after purchasing an additional 106 shares in the last quarter. Finally, True Wealth Design LLC acquired a new position in Natera in the 3rd quarter valued at about $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.